Medical Affairs PharmD Fellowship 2018 - 2020

At Alkermes plc, our employees consistently strive to provide physicians and patients with treatment options that address important unmet needs. Through our scientific expertise, proprietary technologies and global resources, we are uniquely positioned to continue building a portfolio of medicines for major clinical conditions with a focus on central nervous system (CNS) disorders.

Our success to date is evident from our diverse commercial product portfolio, including treatments in major diseases, such as schizophrenia, addiction, diabetes and multiple sclerosis. Beyond our commercial products, we have a promising pipeline of proprietary drug candidates, many in late-stage development. Both our commercialized products and rich pipeline demonstrate our leadership in drug development for CNS diseases, a therapeutic area where we have established expertise and a promise for delivering new treatments.

Our Proprietary Products

Our commercial product portfolio reflects our years of experience in developing innovative and patient-inspired solutions. These unique products address patient needs in major disease areas.

ARISTADA® (aripiprazole lauroxil) extended-release injectable suspension is indicated for the treatment of schizophrenia. It is the first long-acting atypical antipsychotic with once-monthly, six-week and once-every-two-months dosing options.

VIVITROL® (naltrexone for extended-release injectable suspension) is an extended-release injectable formulation of naltrexone. It is the first and only non-narcotic, non-addictive, once-monthly medication for both alcohol and opioid dependence. Designed for once-monthly dosing, VIVITROL eliminates the need for patients to make a daily decision about taking their medicine. Alkermes commercializes VIVITROL in the U.S. Janssen Pharmaceuticals is responsible for the commercialization of VIVITROL in Russia and the Commonwealth of Independent States.

Products Using Alkermes Technologies

We have granted licenses under our proprietary technologies to enable third parties to develop, commercialize and, in some cases, manufacture products for which we receive royalties and/or manufacturing revenues.

AMPYRA® (dalfampridine) is a twice-daily, controlled-release tablet indicated as a treatment to improve walking in patients with multiple sclerosis. AMPYRA is approved in the U.S. where it is marketed by Acorda Therapeutics, Inc. Biogen Inc. holds the rights to develop and commercialize the medication in all markets outside the U.S., where it is sold under the trade name FAMPYRA®.

BYDUREON® (exenatide extended-release for injectable suspension) is a once-weekly therapy for the treatment of type 2 diabetes. BYDUREON is marketed in the U.S. and EU by AstraZeneca.

INVEGA SUSTENNA® (paliperidone palmitate), a Janssen product, is a once-monthly injectable form of paliperidone (INVEGA®) indicated for the treatment of schizophrenia and schizoaffective disorder. INVEGA SUSTENNA is commercialized under the trade name XEPLION® in the EU.

INVEGA TRINZA® (paliperidone palmitate), a Janssen product, is a three-month injectable form of paliperidone (INVEGA®) indicated for the treatment of schizophrenia. INVEGA TRINZA is commercialized under the trade name TREVICTA® in the EU.

RISPERDAL CONSTA® (risperidone), a Janssen product, is a long-acting injectable form of Janssen’s schizophrenia drug risperidone (RISPERDAL®). It is administered once every two weeks for the management of schizophrenia and bipolar I disorder. RISPERDAL CONSTA is commercialized by Janssen in more than 90 countries.

Alkermes plc is a fully

integrated, global bio-

pharmaceutical company

focused on developing

innovative medicines

that address the unmet

needs and challenges

of people living with

serious, chronic diseases.

WEBSITEwww.alkermes.com

TICKER SYMBOLNASDAQ: ALKS

HEADQUARTERSConnaught House1 Burlington RoadDublin 4, Ireland+353 1 772 8000

EMPLOYEESApproximately 1,900 WW

CONTACTSCorporate CommunicationsVoice: +1 781 609 6143 Blair JacksonSenior Vice President, Business DevelopmentVoice: +1 781 609 6594

Description

This new 2-year Doctor of Pharmacy Fellowship Program will support the Medical Affairs team at Alkermes located in Waltham, MA. A partnership with this fellowship with Northeastern University Bouvé College of Health Sciences is currently being developed.

Alkermes Medical Affairs strives to educate healthcare communities and decision makers on the value of our products through the generation and dissemination of scientifically rigorous, accurate, and unbiased clinical, economic, and health outcomes information, with the goal of advancing healthcare. We accomplish this by partnering with internal Alkermes colleagues to catalyze science and knowledge and by serving as a bridge between Alkermes and the healthcare community.

Objectives

] Understand various roles, processes and industry standards involved in the creation and dissemination of medical information in the pharmaceutical industry setting

] Strategically planning, developing and training on standard response letters

] Contribute to the review of internal promotional and medical materials

] Work closely with Medical Affairs team to develop training and scientific education for internal and external stakeholders

] Collaborate with cross-functional teams (regulatory, marketing, sales, legal, clinical development) to provide and communicate the most up to date scientific information as a subject matter expert

] Create, manage and track strategic scientific communication plans in a cross-functional manner

] Partner with Medical Directors to develop scientific materials that align with the scientific communication materials that align with the scientific communication plan (e.g. manuscripts, abstracts, posters, slide decks)

Requirements (Deadline December 1, 2017)

] Curriculum vitae (CV) and cover letter

] Unofficial college transcript

] Three references’ contact information and formal letters of recommendation (per request)

] Candidates must have a Doctor of Pharmacy degree from an ACPE-accredited college of pharmacy by June 30, 2018

How to Apply

Candidates who wish to apply must submit their curriculum vitae (CV), cover letter, and unofficial college transcript. If attending ASHP MidYear Clinical Meeting this material should be submitted through PPS. Applications will be reviewed on a rolling basis until December 1, 2017.

Contact

For further questions, please email pharmdfellowship@alkermes.com

Medical Affairs PharmD Fellowship

AMPYRA® and FAMPYRA® are registered trademarks of Acorda Therapeutics, Inc. ARISTADA® is a trademark of Alkermes Pharma Ireland Limited. BYDUREON® is a registered trademark of Amylin Pharmaceuticals, LLC. RISPERDAL®, RISPERDAL CONSTA®, INVEGA®, INVEGA SUSTENNA®, XEPLION®, INVEGA TRINZA® and TREVICTA® are registered trademarks of Johnson & Johnson. VIVITROL® is a registered trademark of Alkermes, Inc.

CLINICAL DEVELOPMENT PROGRAMS

Preclinical Phase 1 Phase 2Phase 3 FDA Review

At Alkermes plc, we approach the development of new therapeutics with a thoughtful focus on patients’ real-world needs. We are committed to providing patients and caregivers with medicines that offer benefits in terms of safety, efficacy and ultimately, improved health outcomes. This is illustrated by our focused and growing pipeline.

CANDIDATE

ALKS 5461 (Major Depressive Disorder)

Aripiprazole Lauroxil NanoCrystal® Dispersion (Intiation product for ARISTADA®)

ALKS 3831 (Schizophrenia)

ALKS 8700 (Multiple Sclerosis)

ALKS 6428 (Transition From Opioid Dependence*)

ALKS 4230 (Immuno-oncology)

*Transition From Physical Dependence on Opioids to VIVITROL®

At Northeastern, we encourage our students to become engaged citizens of the world, confident, and resourceful people who realize that their knowledge and actions have positive effects on their own lives and those of others. Students ignite their passion for learning and are exposed to the endless possibilities around them through transformative experiential education. The School of Pharmacy provides a dynamic academic environment to guide and support Fellows toward successful careers in the biopharmaceutical industry and offers the opportunity to gain teaching and research experiences in an academic setting. The Northeastern faculty and Alkermes Fellowship preceptors mentor Fellows according to the Fellows’ scholarly and professional interests throughout the two-year program. As a visiting scholar at the School of Pharmacy, a Fellow will:

• Teach and coordinate courses and facilitate seminars and laboratories

• Create and publish scholarly research and review articles

• Present research at scientific and clinical meetings

• Collaborate with fellows and residents in the Boston area